AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment
AstraZeneca has completed its equity investment of $2 billion in Summit Therapeutics and its bispecific antibody drug ivonescimab. AstraZeneca CEO Pascal Soriot stated that the asset could drive the next generation of cancer combinations. Alongside Daiichi Sankyo, AstraZeneca formed a clinical collaboration with Summit to evaluate ivonescimab in combination with Datroway across multiple tumour types. Soriot discussed the strategy from AstraZeneca's new R&D facility in Kendall Square in Cambridge, Massachusetts.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ AstraZeneca completed a $2 billion equity investment in Summit Therapeutics.
- ✓ AstraZeneca and Daiichi Sankyo announced a clinical collaboration with Summit Therapeutics to evaluate Datroway in combination with ivonescimab across multiple tumour types.
- ✓ Pascal Soriot spoke with CNBC from AstraZeneca's new $1 billion R&D facility in Kendall Square in Cambridge, Massachusetts.
- ✓ Ivonescimab is a bispecific antibody drug that targets cancer through dual pathways and showed superiority over Keytruda in clinical trials.
What changed
AstraZeneca completed its equity investment in Summit Therapeutics and announced a new clinical trial collaboration alongside Daiichi Sankyo.
Live updates
-
AstraZeneca Closes $2 Billion Investment in Summit Therapeutics
AstraZeneca has completed its equity investment of $2 billion in Summit Therapeutics and its bispecific antibody drug ivonescimab. AstraZeneca CEO Pascal Soriot stated that the asset could drive the next generation of cancer combinations. Alongside Daiichi Sankyo, AstraZeneca formed a clinical collaboration with Summit to evaluate ivonescimab in combination with Datroway across multiple tumour types. Soriot discussed the strategy from AstraZeneca's new R&D facility in Kendall Square in Cambridge, Massachusetts.
Why it matters
The massive financial commitment highlights big pharma's intense race to secure promising oncology assets. Ivonescimab targets cancer through dual pathways and previously showed superiority over Keytruda in clinical trials. By testing combinations with Datroway, the companies aim to expand the therapeutic utility of these drugs.
What is confirmed
- AstraZeneca completed a $2 billion equity investment in Summit Therapeutics.
- AstraZeneca and Daiichi Sankyo announced a clinical collaboration with Summit Therapeutics to evaluate Datroway in combination with ivonescimab across multiple tumour types.
- Pascal Soriot spoke with CNBC from AstraZeneca's new $1 billion R&D facility in Kendall Square in Cambridge, Massachusetts.
- Ivonescimab is a bispecific antibody drug that targets cancer through dual pathways and showed superiority over Keytruda in clinical trials.
What to watch next
- Results from clinical trials evaluating the combination of ivonescimab and Datroway across multiple tumour types.
- Further announcements regarding the integration of Summit's drug into AstraZeneca's oncology pipeline.
confidence 100%Sources used for this update (11)
- CNBC — AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment
- AstraZeneca — AstraZeneca and Daiichi Sankyo announce clinical collaboration with Summit Therapeutics to evaluate Datroway in combination with ivonescimab across multiple tumour types
- Fierce Pharma — Fierce Pharma Asia—AZ’s $2B bet on ivonescimab; Novo buys Hengrui GLP-1; Merck doubles down on KRAS
- Endpoints News — Summit partners with AstraZeneca and Daiichi; Eccogene earns $50M milestone
- finchannel — AstraZeneca Completes $2 Billion Investment in Summit Therapeutics
- reuters.com — AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination
- AstraZeneca — AstraZeneca completes equity investment in Summit Therapeutics
- Yahoo Finance — SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway Combos
- www.cnbc.com — AstraZeneca CEO says Summit drug could drive next generation ...
- rocketnews.com — AstraZeneca CEO says Summit drug could drive next generation ...
- www.biospace.com — AstraZeneca Completes $2 Billion Equity Investment in Summit ...
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community